AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise

- Adds Imbruvica® a first in class BTK inhibitor approved in multiple indications for blood cancers. - Extensive clinical program with over 50 studies ongoing evaluating Imbruvica® as a treatment for a wide range of additional indications, including early assessments for solid tumors and potential treatment of Graft v Host disease. - Broadens and deepens AbbVie's already robust pipeline, and establishes the combined company as an emerging leader in the hematological oncology space. - Accelerates the company's commercial presence in oncology. - Transaction valued at $261.25 per Pharmacyclics' share, total transaction value of approximately $21 billion - Highly accretive to both revenue and earnings by 2017.

BioSyent Releases Q4 and Full Year 2014 Results - Full Year Sales Up 57%; Pharma Sales Up 63%; Net Income Up 64%; Diluted EPS $0.22 Up 69%; Cash and Short-Term Investments $8.0 Million Up 82%

TORONTO, ONTARIO-- (Feb 25, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Fiscal 2014 and Fourth Quarter (Q4 2014) financial results. Key highlights include:

• Full Year 2014 Sales of $12,211,127 increased by 57% versus 2013
• Revenue has grown at a compound annual growth rate (CAGR) of 63% over the last 3 years
• Full Year 2014 Pharmaceutical Sales of $11,331,269 up 63% versus 2013
• Fourth quarter sales increased by 43% from $2,142,835 in Q4 2013 to $3,058,503 in Q4 2014

Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash

LAVAL, Quebec and RALEIGH, N.C., Feb. 22, 2015

• Salix is the Leader in the Growing U.S. Gastrointestinal Market
• Transaction Creates a New Specialty Platform for Growth
  • Key Promoted Products Showing Strong, Double Digit Volume Growth, Far Exceeding the Market
  • Expected Near-Term Approval for IBS-D Indication of Xifaxan Additional Catalyst for Future Growth
  • Additional Upside from Expected Approval of Relistor Oral as well as Strong Near-Term Pipeline
• Transaction Represents Total Enterprise Value of Approximately $14.5 Billion 

  Published: 23 February 2015

  Written by Editor

  NYSE   M & A   Up on News  

  Read more: Valeant Pharmaceuticals International Inc ( VRX )

Eagle Pharmaceuticals, Inc. Reports Financial Results for Three Month Period Ended December 31, 2014

WOODCLIFF LAKE, N.J.-- Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced its financial results for the transitional three-month period ended December 31, 2014 (the “stub period”). This stub period resulted from the previously-announced change in Eagle’s year end from September 30 to December 31. The company will report financial results of the first quarter of 2015 in May.

Highlights of and subsequent to the three months ended December 31, 2014 include:

• Eagle’s clinical trial demonstrated that our bendamustine hydrochloride product administered in 10 minutes in a 50mL admixture (the “rapid infusion bendamustine product”) is bioequivalent to Treanda^® and has a comparable safety profile.